Loss of CSTA expression is associated with progression of ductal breast cancer in situ to invasive breast cancer [26], presumptively via increased cathepsin B activity which raises the possibility that cathepsin B may be a relevant therapeutic target in aGCT. The gene discussed is CTSB; the disease is invasive breast carcinoma.